B-Lymphocytes
Sanofi returns to Dren Bio for another B‑cell depletion therapy with $100M upfront
Sanofi; Dren Bio; B-cell depletion; autoimmune diseases; strategic collaboration; bispecific antibody; myeloid cell engager; immunology; $100M upfront; licensing deal
Spotlight On: Cabaletta Bio’s Small but Mighty Breakthrough for CAR-T in Autoimmune Arena
Cabaletta Bio; CAR-T therapy; rese-cel; autoimmune diseases; B cell depletion; myositis; systemic lupus erythematosus; systemic sclerosis; pemphigus vulgaris; preconditioning; clinical trial; FDA
Boehringer boards B-cell depletion bandwagon, paying Cue $12M to line up autoimmune attack
Cues, CUE-501, B-Lymphocytes, Boehringer, Depletion, paying, T-Lymphocyte
Cabaletta’s CABA-201 CAR-T Therapy Shows Promising Results in Lupus and Other Autoimmune Diseases
CABA-201, CAR-T therapy, lupus, autoimmune diseases, clinical trials, remission, B cell depletion